Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · IEX Real-Time Price · USD
9.38
-0.34 (-3.50%)
At close: Apr 26, 2024, 4:00 PM
9.70
+0.32 (3.41%)
After-hours: Apr 26, 2024, 7:14 PM EDT
Precision BioSciences Revenue
In the year 2023, Precision BioSciences had annual revenue of $48.73M with 94.15% growth. Revenue in the quarter ending December 31, 2023 was $7.04M, a -33.59% decrease year-over-year.
Revenue (ttm)
$48.73M
Revenue Growth
+94.15%
P/S Ratio
1.33
Revenue / Employee
$447,037
Employees
109
Market Cap
64.87M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 48.73M | 23.63M | 94.15% |
Dec 31, 2022 | 25.10M | -90.43M | -78.28% |
Dec 31, 2021 | 115.53M | 91.24M | 375.72% |
Dec 31, 2020 | 24.29M | 2.05M | 9.20% |
Dec 31, 2019 | 22.24M | 11.36M | 104.34% |
Dec 31, 2018 | 10.88M | 4.40M | 67.84% |
Dec 31, 2017 | 6.48M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Journey Medical | 79.18M |
Personalis | 73.48M |
MDxHealth | 70.19M |
Champions Oncology | 49.22M |
Asensus Surgical | 8.58M |
Silver Spike Investment | 7.76M |
Cue Biopharma | 5.49M |
DTIL News
- 10 days ago - Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics - Business Wire
- 23 days ago - iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S. - Business Wire
- 4 weeks ago - Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update - Business Wire
- 5 weeks ago - Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024 - Business Wire
- 5 weeks ago - Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy - Business Wire
- 7 weeks ago - Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency - Business Wire
- 2 months ago - Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants - Business Wire
- 2 months ago - Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants - Business Wire